How Prevalent Is Cancer in Confirmed Cases With Coronaviruses and Severe Acute Respiratory Syndromes? Publisher Pubmed



Fotouhi M^{1, 2} ; Samami E^{1, 3} ; Mohseni S^{1, 4} ; Nasrollahizadeh A^{1, 2} ; Haddadi M^{1, 2} ; Mirbeyk M^{1, 2} ; Saghazadeh A^{1, 5} ; Rezaei N^{5, 6, 7} Show Affiliations
Source: Advances in Experimental Medicine and Biology Published:2021

Abstract

Novel coronavirus disease 2019 (COVID-19) has posed a crucial hazard to global health. The new species share similarities with the two previously emerged entities: severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) that have caused outbreaks in 2002 and 2012, respectively. Interestingly, all of these coronaviruses can cause potentially fatal respiratory syndromes, though behave differently in patients with cancer compared to patients without cancer. Accordingly, the present chapter aims to, through a systematic investigation, estimate the prevalence of cancer among COVID-19, SARS, and MERS confirmed cases. Our analysis based on data from 78 studies with SARS, MERS, and COVID-19 confirmed cases showed that the prevalence of cancer (4.94%) stands at fourth place after hypertension (20.8%), diabetes (11.39%), and cardiovascular diseases (7.46%). According to the findings of the present study, comorbidities are significantly more common in patients with MERS compared to patients with COVID-19 and SARS, and this was the cancer case as well. Further studies need to address whether or not patients with coronaviruses and cancer are different from patients with coronaviruses without cancer in terms of clinical manifestations, laboratory findings, outcomes, and men to women ratio. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.